Clinical Validation of Discordant Trunk Driver Mutations in Paired Primary and Metastatic Lung Cancer Specimens.

OBJECTIVES To propose an operating procedure for validation of discordant trunk driver mutations. METHODS Concordance of trunk drivers was examined by next-generation sequencing in 15 patients with two to three metastatic lung cancers and 32 paired primary and metastatic lung cancers. RESULTS Tissue identity was confirmed by genotyping 17 single-nucleotide polymorphisms within the panel. All except three pairs showed concordant trunk drivers. Quality assessment conducted in three primary and metastatic pairs with discordant trunk drivers indicates metastasis from a synchronous or remote lung primary in two patients. Review of literature revealed high discordant rates of EGFR and KRAS mutations, especially when Sanger sequencing was applied to examine primary and lymph node metastatic tumors. CONCLUSIONS Trunk driver mutations are highly concordant in primary and metastatic tumors. Discordance of trunk drivers, once confirmed, may suggest a second primary cancer. Guidelines are recommended to establish standard operating procedures for validation of discordant trunk drivers.

[1]  Lisa M Haley,et al.  Clinical Validation of Coexisting Activating Mutations Within EGFR, Mitogen-Activated Protein Kinase, and Phosphatidylinositol 3-Kinase Pathways in Lung Cancers. , 2018, Archives of pathology & laboratory medicine.

[2]  Xueyan Zhang,et al.  Comparison of genetic profiles among primary lung tumor, metastatic lymph nodes and circulating tumor DNA in treatment-naïve advanced non-squamous non-small cell lung cancer patients. , 2018, Lung cancer.

[3]  P. Roepman,et al.  Added Value of 50-Gene Panel Sequencing to Distinguish Multiple Primary Lung Cancers from Pulmonary Metastases: A Systematic Investigation. , 2018, The Journal of molecular diagnostics : JMD.

[4]  Robyn L. Temple-Smolkin,et al.  Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. , 2018, Archives of pathology & laboratory medicine.

[5]  A. Marchevsky,et al.  Next-Generation Sequencing: A Novel Approach to Distinguish Multifocal Primary Lung Adenocarcinomas from Intrapulmonary Metastases. , 2017, The Journal of molecular diagnostics : JMD.

[6]  K. Rabe,et al.  Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer. , 2017, The New England journal of medicine.

[7]  Lisa M Haley,et al.  Clinical mutational profiling of 1006 lung cancers by next generation sequencing. , 2017, Oncotarget.

[8]  Nicolai J. Birkbak,et al.  Tracking the Evolution of Non‐Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[9]  Guang-Biao Zhou,et al.  Multiregion sequencing reveals the intratumor heterogeneity of driver mutations in TP53‐driven non‐small cell lung cancer , 2017, International journal of cancer.

[10]  J. Eshleman,et al.  Clinical mutational profiling of bone metastases of lung and colon carcinoma and malignant melanoma using next‐generation sequencing , 2016, Cancer cytopathology.

[11]  Moon Soo Kim,et al.  Comparison of Epidermal Growth Factor Receptor Mutations between Metastatic Lymph Node Diagnosed by EBUS-TBNA and Primary Tumor in Non-Small Cell Lung Cancer , 2016, PloS one.

[12]  J. Eshleman,et al.  Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective , 2016, BioMed research international.

[13]  C. Férec,et al.  Mutational status of synchronous and metachronous tumor samples in patients with metastatic non-small-cell lung cancer , 2016, BMC Cancer.

[14]  S. Dearden,et al.  Mutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature review , 2015, Journal of experimental & clinical cancer research : CR.

[15]  W Parson,et al.  Inter-laboratory evaluation of SNP-based forensic identification by massively parallel sequencing using the Ion PGM™. , 2015, Forensic science international. Genetics.

[16]  Lisa M Haley,et al.  Challenges posed to pathologists in the detection of KRAS mutations in colorectal cancers. , 2015, Archives of pathology & laboratory medicine.

[17]  Z. Wang,et al.  Meta-analysis of epidermal growth factor receptor and KRAS gene status between primary and corresponding metastatic tumours of non-small cell lung cancer. , 2015, Clinical oncology (Royal College of Radiologists (Great Britain)).

[18]  J. Eshleman,et al.  Lymph node metastases of melanoma: challenges for BRAF mutation detection. , 2015, Human pathology.

[19]  Z. Szallasi,et al.  Spatial and temporal diversity in genomic instability processes defines lung cancer evolution , 2014, Science.

[20]  Lisa M Haley,et al.  Microsatellite Instability Confounds Engraftment Analysis of Hematopoietic Stem-cell Transplantation , 2014, Applied immunohistochemistry & molecular morphology : AIMM.

[21]  Zheng Hu,et al.  EGFR mutation status and its impact on survival of Chinese non-small cell lung cancer patients with brain metastases , 2014, Tumor Biology.

[22]  Alex M. Fichtenholtz,et al.  Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.

[23]  Elisabeth Brambilla,et al.  Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[25]  G. Sauter,et al.  Intratumoral heterogeneity of KRAS mutation is rare in non-small-cell lung cancer. , 2013, Experimental and molecular pathology.

[26]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration , 2012, Briefings Bioinform..

[27]  J. Pfeifer,et al.  Rate of occult specimen provenance complications in routine clinical practice. , 2013, American journal of clinical pathology.

[28]  K. Shimizu,et al.  Heterogeneity of the EGFR mutation status between the primary tumor and metastatic lymph node and the sensitivity to EGFR tyrosine kinase inhibitor in non-small cell lung cancer , 2013, Targeted Oncology.

[29]  W. Ou,et al.  Discordance of epidermal growth factor receptor mutations between primary tumors and corresponding mediastinal nodal metastases in patients operated on for stage N2 non‐small cell lung cancer , 2012, Thoracic cancer.

[30]  M. Matsumoto,et al.  Comparison of epidermal growth factor receptor mutation analysis results between surgically resected primary lung cancer and metastatic lymph nodes obtained by endobronchial ultrasound‐guided transbronchial needle aspiration , 2012, Thoracic cancer.

[31]  T. Mok,et al.  EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas. , 2012, The oncologist.

[32]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[33]  Cheng-Bo Han,et al.  EGFR and KRAS mutations and altered c-Met gene copy numbers in primary non-small cell lung cancer and associated stage N2 lymph node-metastasis. , 2012, Cancer letters.

[34]  J. Koo,et al.  EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases. , 2011, Clinical lung cancer.

[35]  D. Clark,et al.  EGFR and KRAS mutations in metastatic lung adenocarcinomas. , 2011, Human pathology.

[36]  K. Matsuo,et al.  Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Lei-na Sun,et al.  Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice , 2011, Journal of experimental & clinical cancer research : CR.

[38]  Yih-Leong Chang,et al.  Comparison of p53 and Epidermal Growth Factor Receptor Gene Status Between Primary Tumors and Lymph Node Metastases in Non-Small Cell Lung Cancers , 2011, Annals of Surgical Oncology.

[39]  P. Hainaut,et al.  KRAS mutation status in primary nonsmall cell lung cancer and matched metastases , 2010, Cancer.

[40]  S. Monaco,et al.  A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases. , 2010, Human pathology.

[41]  C. Pirker,et al.  EGFR/KRAS/BRAF Mutations in Primary Lung Adenocarcinomas and Corresponding Locoregional Lymph Node Metastases , 2009, Clinical Cancer Research.

[42]  P. Jänne,et al.  Discordance of Molecular Biomarkers Associated with Epidermal Growth Factor Receptor Pathway between Primary Tumors and Lymph Node Metastasis in Non-small Cell Lung Cancer , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[43]  J. Shih,et al.  Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  E. Stathopoulos,et al.  Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC , 2008, British Journal of Cancer.

[45]  E. Raso,et al.  Phenotype of bone metastases of nonsmall cell lung cancer: Epidermal growth factor receptor expression and KRAS mutational status , 2008, Pathology & Oncology Research.

[46]  M. Hermans,et al.  Single nucleotide polymorphism profiling assay to confirm the identity of human tissues. , 2007, The Journal of molecular diagnostics : JMD.

[47]  J. Yokota,et al.  Frequent EGFR mutations in brain metastases of lung adenocarcinoma , 2006, International journal of cancer.